Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial

被引：1
|
作者：
Xiao, Y. [1 ]
Cheng, H. [2 ,3 ]
Wang, L. [1 ]
Yang, L. [1 ]
Yu, X. [1 ]
机构：
[1] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Gynaecol Oncol, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Dept Gynaecol Oncol, Zhengzhou, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
562P
引用
收藏
页码：S805 / S805
页数：1
相关论文
共 50 条
  • [21] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [22] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Qi Yu
    Meng Xiangrui
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [23] Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: A multicenter, open-label, single-arm, phase II trial.
    Qu, Yuan-Yuan
    Guo, Hongqian
    Luo, Hong
    Zou, Qing
    Xing, Ninazeng
    Sun, Zhongquan
    Zhang, Xuepei
    Xia, Shujie
    He, Chaohong
    Zhang, Hailiang
    Cai, Jinling
    Zhang, Xiao
    Wang, Quanren
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: Preliminary results
    Veerasarn, Vutisiri
    Lorvidhaya, Vicharn
    Kamnerdsupaphon, Pimkhuan
    Suntornpong, Nan
    Sangruchi, Supatra
    Lertsanguansinchai, Prasert
    Khorprasert, Chonlakiet
    Sookpreedee, Lak
    Udompunturak, Suthipol
    GYNECOLOGIC ONCOLOGY, 2007, 104 (01) : 15 - 23
  • [25] Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
    Wang, Xuan
    Wu, Xiaowen
    Yang, Yue
    Xu, Weiran
    Tian, Hui
    Lian, Bin
    Chi, Zhihong
    Si, Lu
    Sheng, Xinan
    Kong, Yan
    Zhou, Li
    Mao, Lili
    Li, Siming
    Tang, Bixia
    Yan, Xieqiao
    Bai, Xue
    Guo, Jun
    Cui, ChuanLiang
    EUROPEAN JOURNAL OF CANCER, 2023, 182 : 57 - 65
  • [26] Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.
    Guo, Honghai
    Ding, Ping'an
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Zhang, Ze
    Zheng, Tao
    Zhang, Zhidong
    Wang, Dong
    Tan, Bibo
    Zhao, Xuefeng
    Li, Yong
    Zhao, Qun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16091 - E16091
  • [27] Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial
    Chen, Maohui
    Huang, Yizhou
    Zhang, Shuliang
    Zheng, Yixiong
    Zeng, Taidui
    Chen, Chun
    Zheng, Bin
    BMJ OPEN, 2024, 14 (02):
  • [28] Neoadjuvant camrelizumab followed by concurrent camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, phase II study
    Sheng, Yinliang
    Meng, Xiangrui
    Zhang, Chunyang
    Shan, Zhengzheng
    Li, Feng
    Wu, Bin
    Xu, Mengli
    Li, Aijia
    Guan, Lulu
    Chen, Lidong
    Sun, Shuzhen
    Ma, Yihui
    Lu, Taiying
    Zhao, Song
    Fan, Qingxia
    Qi, Yu
    Wang, Feng
    JOURNAL OF THORACIC DISEASE, 2024, 16 (08) : 5337 - 5347
  • [29] Camrelizumab plus apatinib combined with POF in patients with untreated advanced gastric cancer (UAGC): A singlecenter, open-label, single-arm, phase II trial (SYLT-017)
    Su, L.
    Zhao, S.
    Lin, P.
    Yin, Y.
    Lin, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1119 - S1120
  • [30] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
    Wang, Feng
    Qi, Yu
    Meng, Xiangrui
    Fan, Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345